Scholars Central

Conference abstractPublished 13 Jul 2015

Understanding responses to therapy and rationale for combination strategies

Authors: Zachary A Cooper

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There have been significant advances in melanoma therapy over the past several years with several molecularly targeted and immunotherapeutic agents recently FDA-approved for use the treatment of patients with metastatic disease. However with these advances, we are posed with therapeutic dilemmas with regard to timing and sequence of therapy. Namely, there is significant debate as to whether to begin treatment with targeted therapy versus immunotherapy upfront and at which point to change treatment strategy. This is highly relevant as each of these treatments as mono-therapy have significant limitations. As a group, we have focused on better understanding response and resistance to therapy through longitudinal tissue and blood analyses in patients on targeted therapy and immunotherapy. We have worked with investigators worldwide to better understand response and resistance to therapy and have gained critical insights that have led to therapeutic inroads for patients with melanoma. This includes the use of combination strategies such as adding immune checkpoint blockade to a backbone of molecularly targeted therapy. Clinical trials combining these strategies are currently underway and it is becoming increasingly apparent that complexities exist with regard to these combinations. A better understanding of mechanisms of response to combination strategies through translational research is critical and is best performed on longitudinal patient samples during the course of therapy which may inform (and be informed by) parallel murine studies. Ultimately, ideal combination approaches will be built on a deep understanding of molecular and immune effects of each therapy in isolation as well as in combination.

Subjects

Dermatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Dermatology Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Dermatology Research
  • SubjectDermatology
  • BylineArticles whose byline prints “Zachary A Cooper”